Gyre Therapeutics, Inc.

Total Valuation

Gyre Therapeutics, Inc. carries a market capitalization of 551.90M, placing it among publicly traded companies globally. Its enterprise value stands at 4.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Gyre Therapeutics, Inc. currently has 91.34M shares outstanding.

Valuation Ratios

Gyre Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 2,679.12. The price-to-sales ratio is 37.23, and the price-to-book ratio stands at -56.17.

Enterprise Valuation

On an enterprise value basis, Gyre Therapeutics, Inc. trades at an EV/EBITDA multiple of 856.37 and an EV/FCF ratio of 775.22. The EV/Sales ratio of 37.12 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,798.16 provides insight into valuation relative to core operating earnings.

Financial Position

Gyre Therapeutics, Inc. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Gyre Therapeutics, Inc. has paid 4.28M in income taxes, reflecting an effective tax rate of 758.16.

Stock Price Statistics

Gyre Therapeutics, Inc.'s stock has declined approximately -30.77859% over the past 52 weeks. The 50-day moving average sits at 7.09, while the 200-day moving average is 7.60.

Income Statement

Over the trailing twelve months, Gyre Therapeutics, Inc. generated 117.05M in revenue and converted that into -6.36M in net income, yielding earnings per share of -0.04. EBITDA reached 5.07M, while operating income came in at 2.42M.

Balance Sheet

Gyre Therapeutics, Inc. holds 49.81M in cash and equivalents against 823,000.00 in total debt, resulting in a net debt position of -37.50M. Total book value stands at -77.58M, with working capital of 71.94M providing operational flexibility.

Cash Flow

Gyre Therapeutics, Inc. produced 4.32M in operating cash flow over the past twelve months. After subtracting -1.28M in capital expenditures, free cash flow totaled 3.03M - equivalent to 0.03 per share.

Margins

Gyre Therapeutics, Inc. operates with a gross margin of 95.09, reflecting its pricing power and cost economics. The operating margin of 2.06 and net profit margin of -5.44 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Gyre Therapeutics, Inc.'s most recent stock split took place on October 31, 2023 with a 15:1 split ratio.

Scores

Gyre Therapeutics, Inc. posts an Altman Z-Score of 105.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.